Biofrontera AGFRA:B8FK 56 Interest Coverage is 1.50 as of Mar. 2026, which is 99% below its 10-year median of 164.25. GuruFocus rates FRA:B8FK with a GF Score™ of 56/100 and a GF Value™ of €2.29 (Fairly Valued). The stock has 4 warning signs investors should review. Among 686 Drug Manufacturers companies, Biofrontera AG ranks worse than 145772.45% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Biofrontera AG's
Operating Income
for the
three
months ended in Mar. 2026 was €0.01 Mil. Biofrontera AG's Interest Expense for the
three
months ended in Mar. 2026 was €-0.01 Mil.
Biofrontera AG's interest coverage for the quarter that ended in Mar. 2026 was 1.50.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Biofrontera AG's Interest Coverage or its related term are showing as below:
FRA:B8FK's Interest Coverage is not ranked *
in the Drug Manufacturers industry.
Industry Median: 12.725 * Ranked among companies with meaningful Interest Coverage only.
Biofrontera AG (FRA:B8FK) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Biofrontera AG Interest Coverage Related Terms
Biofrontera AG Interest Coverage Historical Data
* Premium members only.
The historical data trend for Biofrontera AG's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
FRA:B8FK vs ZTS, UTHR, VTRS: Interest Coverage Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera AG's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofrontera AG Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofrontera AG's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Biofrontera AG's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofrontera AG (FRA:B8FK) has a Interest Coverage of 1.50 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Biofrontera AG and its competitors. This is 99% below median its historical median of 164.25. According to the industry distribution chart, Biofrontera AG ranks #999999 out of 686 companies in the Drug Manufacturers industry.
Is Biofrontera AG's Interest Coverage too high?
Biofrontera AG's current Interest Coverage of 1.50 is 99% below median its 10-year median of 164.25. The Drug Manufacturers industry median Interest Coverage is 12.73. Biofrontera AG's value of 1.50 is 88.2% below this industry median. Based on the distribution chart, Biofrontera AG ranks #999999 out of 686 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Biofrontera AG has a GF Score™ of 56/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biofrontera AG's Interest Coverage compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biofrontera AG ranks #999999 out of 686 companies for Interest Coverage. This places Biofrontera AG in the lower half of its industry. The industry median Interest Coverage is 12.73. Biofrontera AG's value of 1.50 is 88.2% below this benchmark. While the company's 10-year median is 164.25 vs. the industry median of 12.73, Biofrontera AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.73, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biofrontera AG's current Interest Coverage of 1.50 is 88.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Biofrontera AG and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofrontera AG's current Interest Coverage is 1.50, which is 99% below median its own 10-year median of 164.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofrontera AG stock overvalued right now?
Based on GuruFocus' analysis, Biofrontera AG (FRA:B8FK) is currently considered Fairly Valued. The stock's GF Value™ is €2.29, compared to a current price of €2.24 — trading 2.2% below its estimated fair value. The current Interest Coverage is 1.50, which is 99% below median its 10-year median of 164.25 and 88.2% below the Drug Manufacturers industry median of 12.73. Biofrontera AG's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Biofrontera AG (FRA:B8FK), the current Interest Coverage is 1.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofrontera AG (FRA:B8FK) Overvalued in 2026?
Based on GuruFocus' analysis, Biofrontera AG stock appears to be undervalued.
The current stock price of €2.24 is trading 2.2% below its estimated GF Value™ of €2.29.
GuruFocus considers Biofrontera AG to be Fairly Valued.
Key valuation signals for FRA:B8FK:
Interest Coverage: 1.50 (99% below median its 10-year median of 164.25)
GF Value™: €2.29 vs. price of €2.24 (2.2% below fair value)
Industry Position: 88.2% below the Drug Manufacturers median (#999999 of 686)
No single metric tells the full story. See the FRA:B8FK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
56GF Score
Get the complete analysis for FRA:B8FK
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:B8FK has been successfully added to your 
